Serum chemokine-release profiles in AML-patients might contribute to predict the clinical course of the disease
Autor: | D. Fischbacher, Christine Grabrucker, D. Kraemer, Amy E. Liepert, H. J. Kolb, J. Dreyssig, Arndt Borkhardt, C.-H. Koehne, M. Freudenreich, F. Schuster, M. Merle, Andreas Kremser, Tanja Kroell, Christoph Schmid, H. M. Schmetzer |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Adult Male Chemokine Acute Myeloid Leukemia Chemokines Dendritic Cells Immunotherapy T-cells Angiogenesis medicine.medical_treatment Immunology Disease CCL2 CCL5 03 medical and health sciences 0302 clinical medicine Immune system Medicine Humans Interleukin 8 Aged Aged 80 and over biology business.industry General Medicine Middle Aged Prognosis Leukemia Myeloid Acute 030104 developmental biology 030220 oncology & carcinogenesis biology.protein Cytokines Female business Stem Cell Transplantation |
Zdroj: | Immunol. Invest. 49, 365-385 (2019) |
Popis: | In cancer or hematologic disorders, chemokines act as growth- or survival factors, regulating hematopoiesis and angiogenesis, determining metastatic spread and controlling leukocyte infiltration into tumors to inhibit antitumor immune responses. The aim was to quantify the release of CXCL8, −9, −10, CCL2, −5, and IL-12 in AML/MDS-pts’ serum by cytometric bead array and to correlate data with clinical subtypes and courses. Minimal differences in serum-levels subdivided into various groups (e.g. age groups, FAB-types, blast-proportions, cytogenetic-risk-groups) were seen, but higher release of CXCL8, −9, −10 and lower release of CCL2 and −5 tendentially correlated with more favorable subtypes ( |
Databáze: | OpenAIRE |
Externí odkaz: |